The relationship between diabetes mellitus and oral lesions: A cross-sectional study based on cohort data of Adults in Southeastern Iran

Document Type : Original Article

Authors

1 School of Dentistry, Michigan University,Michigan, Ann Arbor, USA.

2 Dental Private Practice, Non Non-communicable Diseases Research Center, Rafsenjan University of Medical Sciences, Rafsenjan, Iran

3 Pistachio Safety Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran, and Clinical Research Development Unit (CRDU), Niknafs Hospital, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

4 Social Determinants of Health Research Center, Rafsanjan University of Medical Sciences,Rafsanjan, Iran, and Department of Epidemiology and Biostatistics, School of Health, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

5 Non-Communicable Diseases Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran, and Department of Oral Medicine, Dental School, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

6 Oral Medicine Department, Kerman University of Medical Sciences, Kerman, Iran

7 Non-Communicable Diseases Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran, and Department of Oral Medicine, School of Dentistry, Kerman University of Medical Sciences, Kerman, Iran

Abstract

Background: Our study investigated the relationship between the prevalence of oral lesions and diabetes mellitus (DM) in Rafsanjan, located in southeastern Iran.
Method: This cross-sectional study drew upon baseline data from the Oral Health Branch of Rafsanjan Cohort Study (OHBRCS), a component of the broader Rafsanjan Cohort Study (RCS). The RCS, initiated in 2015 in Rafsanjan, is an ongoing prospective epidemiological investigation within the framework of the Prospective Epidemiological Research Studies in Iran (PERSIAN), with follow-up phases currently in progress. Thorough oral examinations were performed by trained dental professionals, who identified oral lesions through clinical assessment. Data concerning DM was collected from participants’ self-reported medical histories, subsequently corroborated by a physician. To assess the association between DM and oral lesions, both univariate and multivariate dichotomous logistic regression analyses were conducted.
Results: Of the 8640 participants examined (mean age = 49.95 years), 1698 (19.65%) individuals were diagnosed with DM. The study also identified the prevalence of several oral conditions, encompassing diffuse oral pigmentation (13.91%), non-diffuse pigmentation (11.5%), candidiasis (10.42%), red and white lesions (8.24%), leukoplakia (7.48%), herpes (5.06%), oral exophytic lesions (4.48%), and erythroplakia (0.94%). In an adjusted analysis, DM was correlated with a reduced probability of diffuse oral pigmentation (odds ratio [OR]: 0.8; 95% confidence interval [CI]: 0.69-0.95). Additionally, within the same adjusted model, diabetic patients receiving insulin therapy demonstrated a significantly elevated likelihood (6.63 times) of developing erythroplakia when contrasted with those not undergoing insulin therapy (OR: 6.63; 95% CI: 1.23-36.26).
Conclusion: Diabetic patients exhibited a reduced incidence of diffuse oral pigmentation. Conversely, erythroplakia was observed more frequently in diabetic patients undergoing insulin therapy. Further long-term investigations are necessary to substantiate these preliminary findings.

Keywords

Main Subjects

References

1. Lamster IB, Lalla E, Borgnakke WS, Taylor GW. The
relationship between oral health and diabetes mellitus. J Am
Dent Assoc. 2008;139 Suppl:19S-24S. doi: 10.14219/jada.
archive.2008.0363.
2. Remschmidt B, Pau M, Gaessler J, Zemann W, Jakse N, Payer
M, et al. Diabetes mellitus and oral cancer: a retrospective
study from Austria. Anticancer Res. 2022;42(4):1899-903.
doi: 10.21873/anticanres.15666.
3. Rezvaninejad R, Rezvaninejad R, Azdanesh A, Sheybani-
Arani M, Salimi Asl A, Vahidipour MA, et al. Prevalence of
mucosal lesions in people consuming chewable tobacco in
Hormozgan province, Iran. Tob Health. 2022;1(3):132-7. doi:
10.34172/thj.2022.21.
4. Varghese C, Onuma O, Johnson W, Brainin M, Hacke
W, Norrving B. Organizational update: World Health
Organization. Stroke. 2017;48(12):e341-2. doi: 10.1161/
strokeaha.117.016941.
5. Mohammadi M, Vaisi Raiegani AA, Jalali R, Ghobadi A, Salari
N. The prevalence of retinopathy among type 2 diabetic
patients in Iran: a systematic review and meta-analysis. Rev
Endocr Metab Disord. 2019;20(1):79-88. doi: 10.1007/
s11154-019-09490-3.
6. Mortazavi H. How can we reduce diagnostic errors related
to oral lesions in healthcare centers? J Oral Health Oral
Epidemiol. 2024;13(2):43-4. doi: 10.34172/johoe.2405.1647.
7. Rezvaninejad R, Dadmehr M, Rezvaninejad R. Prevalence of
oral manifestations in systemic lupus erythematosus patients
referred to Shahid Mohammadi hospital in 2018-2019.
Jundishapur J Health Sci. 2021;13(2):e116144. doi: 10.5812/
jjhs.116144.
8. Rahimnejad M, Rezvaninejad R, Rezvaninejad R, França R.
Biomaterials in bone and mineralized tissue engineering using
3D printing and bioprinting technologies. Biomed Phys Eng
Express. 2021;7(6). doi: 10.1088/2057-1976/ac21ab.
9. Abati S, Sandri GF, Finotello L, Polizzi E. Differential
diagnosis of pigmented lesions in the oral mucosa: a clinical
based overview and narrative review. Cancers (Basel).
2024;16(13):2487. doi: 10.3390/cancers16132487.
10. Rohani B. Oral manifestations in patients with diabetes
mellitus. World J Diabetes. 2019;10(9):485-9. doi: 10.4239/
wjd.v10.i9.485.
11. Kakoei S, Navabi N, Aghaabbasi S, Hashemipour MA. Oral
health related quality of life in patients with diabetes mellitus
type 2 in the year 2012. J Oral Health Oral Epidemiol.
2016;5(4):186-91.
12. Moannaei M, Nazari G, Salarpour E, Rezvaninejad FS,
Moaddeli M. Investigating oral and dental health and quality
of life: a cross-sectional study. Tob Health. 2024;3(2):125-32.
doi: 10.34172/thj.1250.
13. D’Aiuto F, Gable D, Syed Z, Allen Y, Wanyonyi KL, White
S, et al. Evidence summary: the relationship between oral
diseases and diabetes. Br Dent J. 2017;222(12):944-8. doi:
10.1038/sj.bdj.2017.544.
14. Ponte E, Tabaj D, Maglione M, Melato M. Diabetes mellitus
and oral disease. Acta Diabetol. 2001;38(2):57-62. doi:
10.1007/s005920170014.
15. Farrasoya M, Annisa RN, Rochmawati M, Tanjungsari NK.
Oral manifestations in patients with uncontrolled type 1
diabetes mellitus. Makassar Dent J. 2024;13(1):74-7. doi:
10.35856/mdj.v13i1.847.
16. Sanjeeta N, Sivapathasundharam B, Nandini DB. Oral
lesions and periodontal status in diabetics and nondiabetics:
a hospital-based study. J Oral Maxillofac Pathol.
2022;26(3):419. doi: 10.4103/jomfp.jomfp_37_21.
17. Hakimi H, Ahmadi J, Vakilian A, Jamalizadeh A, Kamyab Z,
Mehran M, et al. The profile of Rafsanjan Cohort Study. Eur
J Epidemiol. 2021;36(2):243-52. doi: 10.1007/s10654-020-
00668-7.
18. Sardari F, Sharifi Z, Salari Sedigh S, Khalili P, Jamali Z, Ayoobi
F, et al. The profile of Oral Health Branch of Rafsanjan Cohort
Study (OHBRCS) in Rafsanjan city, southeast of Iran. Prev Med
Rep. 2023;36:102513. doi: 10.1016/j.pmedr.2023.102513.
19. Khalili P, Ayoobi F, Mohamadi M, Jamalizadeh A, La Vecchia
C, Esmaeili-Nadimi A. Effect of opium consumption on
cardiovascular diseases - a cross- sectional study based on
data of Rafsanjan Cohort Study. BMC Cardiovasc Disord.
2021;21(1):2. doi: 10.1186/s12872-020-01788-4.
20. Poustchi H, Eghtesad S, Kamangar F, Etemadi A, Keshtkar
AA, Hekmatdoost A, et al. Prospective Epidemiological
research studies in Iran (the PERSIAN Cohort Study): rationale,
objectives, and design. Am J Epidemiol. 2018;187(4):647-55.
doi: 10.1093/aje/kwx314.
21. Glick M, Greenberg MS, Lockhart PB, Challacombe SJ.
Introduction to oral medicine and oral diagnosis: patient
evaluation. In: Glick M, Greenberg MS, Lockhart PB,
Challacombe SJ, eds. Burket’s Oral Medicine. John Wiley &
Sons; 2021. p. 1-18. doi: 10.1002/9781119597797.ch1.
22. Lu SY. Oral candidosis: pathophysiology and best practice for
diagnosis, classification, and successful management. J Fungi
(Basel). 2021;7(7):555. doi: 10.3390/jof7070555.
23. Machón M, Larrañaga I, Dorronsoro M, Vrotsou K, Vergara
I. Health-related quality of life and associated factors in
functionally independent older people. BMC Geriatr.
2017;17(1):19. doi: 10.1186/s12877-016-0410-3.
24. Madathil J, Salim HP, Balan A, Radhakrishnan C, Kumar NR.
Prevalence of oral lesions in patients with type 2 diabetes in
north Kerala population. J Diabetol. 2020;11(1):32-8. doi:
10.4103/jod.jod_7_19.
25. Skamagas M, Breen TL, LeRoith D. Update on diabetes
mellitus: prevention, treatment, and association with oral
diseases. Oral Dis. 2008;14(2):105-14. doi: 10.1111/j.1601-
0825.2007.01425.x.
26. Collin HL, Niskanen L, Uusitupa M, Töyry J, Collin P, Koivisto
AM, et al. Oral symptoms and signs in elderly patients with type
2 diabetes mellitus. A focus on diabetic neuropathy. Oral Surg
Oral Med Oral Pathol Oral Radiol Endod. 2000;90(3):299-
305. doi: 10.1067/moe.2000.107536.
27. Beikler T, Flemmig TF. Implants in the medically compromised
patient. Crit Rev Oral Biol Med. 2003;14(4):305-16. doi:
10.1177/154411130301400407.
28. Davis TM, Bruce DG, Curtis BH, Barraclough H, Davis
WA. The relationship between intensification of blood
glucose-lowering therapies, health status and quality of life
in type 2 diabetes: the Fremantle Diabetes Study Phase II.
Diabetes Res Clin Pract. 2018;142:294-302. doi: 10.1016/j.
diabres.2018.05.047.
29. Sreeja C, Ramakrishnan K, Vijayalakshmi D, Devi M, Aesha
I, Vijayabanu B. Oral pigmentation: a review. J Pharm
Bioallied Sci. 2015;7(Suppl 2):S403-8. doi: 10.4103/0975-
7406.163471.
30. Lenane P, Powell FC. Oral pigmentation. J Eur Acad
Dermatol Venereol. 2000;14(6):448-65. doi: 10.1046/j.1468-
3083.2000.00143.x.
31. Mohsin SF, Ahmed SA, Fawwad A, Basit A. Prevalence of
oral mucosal alterations in type 2 diabetes mellitus patients
attending a diabetic center. Pak J Med Sci. 2014;30(4):716-9.
doi: 10.12669/pjms.304.5220.
32. Lambertini M, Patrizi A, Ravaioli GM, Dika E. Oral
pigmentation in physiologic conditions, post-inflammatory
affections and systemic diseases. G Ital Dermatol Venereol.
2018;153(5):666-71. doi: 10.23736/s0392-0488.17.05619-x.
33. Ship JA. Diabetes and oral health: an overview. J Am Dent
Assoc. 2003;134 Spec No:4s-10s. doi: 10.14219/jada.
archive.2003.0367.
34. Nguyen TD, Nguyen TT, Tran QV. The incidence of oral
candidiasis in patients with diabetes mellitus: a cross-sectional
study in Southern Vietnam. J Crit Rev. 2020;7(4):82-6. doi:
10.31838/jcr.07.04.17.
35. Al-Maskari AY, Al-Maskari MY, Al-Sudairy S. oral
manifestations and complications of diabetes mellitus: a
review. Sultan Qaboos Univ Med J. 2011;11(2):179-86.
36. Martorano-Fernandes L, Dornelas-Figueira LM, Marcello-
Machado RM, de Brito Silva R, Magno MB, Maia LC, et
al. Oral candidiasis and denture stomatitis in diabetic
patients: systematic review and meta-analysis. Braz Oral
Res. 2020;34:e113. doi: 10.1590/1807-3107bor-2020.
vol34.0113.
37. Sampath A, Weerasekera M, Dilhari A, Gunasekara C,
Bulugahapitiya U, Fernando N, et al. Type 2 diabetes mellitus
and oral Candida colonization: analysis of risk factors in a Sri
Lankan cohort. Acta Odontol Scand. 2019;77(7):508-16. doi:
10.1080/00016357.2019.1607547.
38. Mishra N, Trivedi A, Gajdhar SK, Bhagwat H, Khutwad
GK, Mall PE, et al. Correlation of blood glucose levels,
salivary glucose levels and oral colony forming units of
Candida albicans in type 2 diabetes mellitus patients. J
Contemp Dent Pract. 2019;20(4):494-8. doi: 10.5005/jpjournals-
10024-2545.
39. Gong Y, Wei B, Yu L, Pan W. Type 2 diabetes mellitus and
risk of oral cancer and precancerous lesions: a meta-analysis
of observational studies. Oral Oncol. 2015;51(4):332-40. doi:
10.1016/j.oraloncology.2015.01.003.
40. Dikshit RP, Ramadas K, Hashibe M, Thomas G, Somanathan
T, Sankaranarayanan R. Association between diabetes mellitus
and pre-malignant oral diseases: a cross sectional study in
Kerala, India. Int J Cancer. 2006;118(2):453-7. doi: 10.1002/
ijc.21345.
41. Ramos-Garcia P, Del Mar Roca-Rodriguez M, Aguilar-
Diosdado M, Gonzalez-Moles MA. Diabetes mellitus and
oral cancer/oral potentially malignant disorders: a systematic
review and meta-analysis. Oral Dis. 2021;27(3):404-21. doi:
10.1111/odi.13289.
42. Ujpál M, Matos O, Bíbok G, Somogyi A, Szabó G, Suba
Z. Diabetes and oral tumors in Hungary: epidemiological
correlations. Diabetes Care. 2004;27(3):770-4. doi: 10.2337/
diacare.27.3.770.
43. Aslam S, Ghafoor S. Insulin-like growth factor-I signaling plays
a pivotal role in the development of oral premalignant lesions
in patients with diabetes mellitus. BioMedica. 2022;38(3):129-
33. doi: 10.51441/BioMedica/5-759.
44. de Souza Bastos A, Leite AR, Spin-Neto R, Nassar PO,
Massucato EM, Orrico SR. Diabetes mellitus and oral mucosa
alterations: prevalence and risk factors. Diabetes Res Clin
Pract. 2011;92(1):100-5. doi: 10.1016/j.diabres.2011.01.011.
45. Albrecht M, Bánóczy J, Dinya E, Tamás G Jr. Occurrence
of oral leukoplakia and lichen planus in diabetes mellitus. J
Oral Pathol Med. 1992;21(8):364-6. doi: 10.1111/j.1600-
0714.1992.tb01366.x.
46. Dietrich T, Reichart PA, Scheifele C. Clinical risk factors
of oral leukoplakia in a representative sample of the US
population. Oral Oncol. 2004;40(2):158-63. doi: 10.1016/
s1368-8375(03)00145-3.
Journal of Oral Health and Oral Epidemiology
Volume 14, Issue 1
January 2025
Pages 1-10

Files

History

  • Receive Date: 15 October 2024
  • Revise Date: 18 February 2025
  • Accept Date: 18 February 2025

Share

How to cite

Statistics